917835-93-9

Usage

Uses

Used in Pharmaceutical Synthesis:
(2R,4S)-Boc-4-hydroxypiperidine-2-carboxylic acid is used as a key intermediate in the synthesis of 1,2-dihydroquinolin-2-one and 1,2-dihydroquinoxalin-2-one derivatives. These derivatives possess potent antibacterial properties, making them valuable in the development of new antibiotics to combat bacterial infections.
Used in Organic Synthesis:
As a chiral building block, (2R,4S)-Boc-4-hydroxypiperidine-2-carboxylic acid is utilized in the synthesis of various enantioselective compounds. Its unique stereochemistry and functional groups allow for the creation of complex molecules with potential applications in the pharmaceutical, agrochemical, and materials science industries.
Used in Research and Development:
In academic and industrial research settings, (2R,4S)-Boc-4-hydroxypiperidine-2-carboxylic acid serves as a starting material for exploring new synthetic routes and methodologies. Its reactivity and structural features make it an attractive candidate for studying novel reactions and developing innovative synthetic strategies.
Used in Drug Discovery:
(2R,4S)-Boc-4-hydroxypiperidine-2-carboxylic acid's ability to be modified and incorporated into diverse molecular frameworks positions it as a valuable tool in drug discovery. Researchers can use (2R,4S)-Boc-4-hydroxypiperidine-2-carboxylic acid to design and optimize new drug candidates with improved potency, selectivity, and pharmacokinetic properties.
Overall, (2R,4S)-Boc-4-hydroxypiperidine-2-carboxylic acid is a multifaceted chemical entity with applications spanning across various fields, from pharmaceutical development to materials science, highlighting its importance in modern chemical research and innovation.

Upstream product

• 14228-16-1 2R-carboxy-4R-hydroxypiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 175476-93-4 (1S,5R)-2-(tert-butoxycarbonyl)-6-oxa-2-azabicyclo<3.2.1>octan-7-one 
• 1218818-60-0 1-phenylethylammonium (2R,4R)-1-(tert-butoxycarbonyl)-4-hydroxypiperidine-2-carboxylate 
• 175671-49-5 (2R,4R)-4-hydroxy-2-piperidinecarboxylic acid 
• 198646-60-5 (S)-1-(tertbutyloxycarbonyl)-4-oxo-piperidine-2-carboxylic acid 
• 441044-14-0 phenylmethanaminium (2R,4R)-1-(tert-butoxycarbonyl)-4-hydroxypiperidine-2-carboxylate 
• 1031883-65-4 dimethyl (2S,4R)-4-hydroxypiperidine-1,2-dicarboxylate 
• 1204587-85-8 dimethyl (R)-4-tert-butoxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate 
• 1204587-88-1 dimethyl (2S,4R)-4-tert-butoxypiperidine-1,2-dicarboxylate 
• 1032237-00-5 (2S,4R)-4-hydroxypiperidine-2-carboxylic acid hydrochloride 
• 441044-14-0 (2S,4S)-N-Boc-4-hydroxypiperidine-2-carboxylic acid benzylamine salt 
• 475504-28-0 4-formyloxy-(S)-pipecolic acid methyl ester 
• 78553-47-6 methyl (2S)-2-[N-(benzyloxycarbonyl)amino]pent-4-enoate 

Downstream Products

• 14228-16-1 2R-carboxy-4R-hydroxypiperidine 
• 1579996-65-8 (2S,4S)-N-((S)-1-cyano-2-(4-(2-methyl-1-oxoisoindolin-5-yl)phenyl)ethyl)-4-hydroxypiperidine-2-carboxamide 

Relevant academic research and scientific papers

Enantioselective Synthesis of cis and trans 4-Aminopipecolic Acids as γ-Amino Acids for the Construction of Cyclic RGD-Containing Peptidomimetics Antagonists of αVβ3 Integrin

A stereodivergent strategy to obtain enantiopure cis and trans 4-aminopipecolic acids (4-APAs) in a suitably protected form for peptide synthesis has been devised starting from a common, known precursor in turn easily prepared from commercial (R)-4-cyano-3-hydroxybutyric acid ethyl ester. The two isomers were efficiently obtained in 40 percent and 23 percent overall yields, respectively, in seven and ten steps. To demonstrate their usefulness in peptidomimetic synthesis, both 4-APA isomers were incorporated as γ-amino acids in a cyclic RGD-containing sequence, although for the trans 4-APA isomer a further amino acid in the sequence (L-Phe) was needed to allow ring closure. The two cyclopeptides were tested as αVβ3 integrin antagonists in comparison with cilengitide.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

TUBULYSIN ANALOGUES AS ANTICANCER AGENTS AND PAYLOADS FOR ANTIBODY-DRUG CONJUGATES AND METHODS OF TREATMENT THEREWITH

In one aspect, the present disclosure provides tubulysin analogs of the formula (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect

COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION

The present invention relates to a class of novel heterocyclic compounds, to pharmaceutical compositions comprising the compounds and their use in the treatment of kinetoplastid infections.

Improved Total Synthesis of Tubulysins and Design, Synthesis, and Biological Evaluation of New Tubulysins with Highly Potent Cytotoxicities against Cancer Cells as Potential Payloads for Antibody-Drug Conjugates

Improved, streamlined total syntheses of natural tubulysins such as V (Tb45) and U (Tb46) and pretubulysin D (PTb-D43), and their application to the synthesis of designed tubulysin analogues (Tb44, PTb-D42, PTb-D47-PTb-D49, and Tb50-Tb120), are described.

PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS

The present invention provides a compound of the Formula (I): wherein X, R, R1,R2,R3, R4,R5,R6, R7, R8, and R9 are as defined herein, or a pharmaceutically acceptable salt thereof.

INHIBITORS OF SPHINGOSINE KINASE 1

The invention relates to compounds of Formula (I). Compounds of the present invention are inliibitors of sphingosine kinase 3, and are useful in the treatment of various disorders and conditions, such as inflammatory disorders

Asymmetric synthesis of cis-4- and trans-3-hydroxypipecolic acids

Enantioselective syntheses of cis-4- and trans-3-hydroxypipecolic acids from 2,3-epoxy-5-hexen-1-ol (7) are described. Regioselective C-3 or C-2 ring opening of the epoxide by the appropriate nitrogen nucleophile is the key step in each route. As enantiom

Discovery and synthesis of HIV integrase inhibitors: Development of potent and orally bioavailable N-methyl pyrimidones

The human immunodeficiency virus type-1 (HIV-1) encodes three enzymes essential for viral replication: a reverse transcriptase, a protease, and an integrase. The latter is responsible for the integration of the viral genome into the human genome and, therefore, represents an attractive target for chemotherapeutic intervention against AIDS. A drug based on this mechanism has not yet been approved. Benzyl-dihydroxypyrimidine-carboxamides were discovered in our laboratories as a novel and metabolically stable class of agents that exhibits potent inhibition of the HIV integrase strand transfer step. Further efforts led to very potent compounds based on the structurally related N-Me pyrimidone scaffold. One of the more interesting compounds in this series is the 2-N-Me-morpholino derivative 27a, which shows a CIC95 of 65 nM in the cell in the presence of serum. The compound has favorable pharmacokinetic properties in three preclinical species and shows no liabilities in several counterscreening assays.

QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS

The invention concerns quinazoline derivatives of the Formula (I), or pharmaceutically acceptable salts thereof: I wherein each of R1, R2, R3, R4 and m are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula (I) are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.